J. Brian Stalter

Special Counsel
Full contact info

About Brian

Brian Stalter has been structuring and negotiating complex life sciences transactions for over 20 years. Most recently, Brian was general counsel at Cabaletta Bio, a public biotechnology company in Philadelphia focused on the development of cell therapies for the treatment of auto-immune disease. Prior to Cabaletta, Brian was vice president and assistant general counsel at Bristol-Myers Squibb (BMS), leading a team that was responsible for a broad range of corporate partnering arrangements for BMS on a worldwide basis, including licensing agreements, collaborative research and development agreements, academic collaborations and co-commercialization arrangements. During his 14-year career at BMS, Brian handled several transformative deals, including BMS’ cardiovascular alliance with Pfizer on ELIQUIS, its partnership in immuno-oncology with Ono Pharmaceutical Co. on OPDIVO and other I-O agents, with Protein Design Labs (now Abbvie) on EMPLICITI in hematology, and in neuroscience with Otsuka on ABILIFY. Prior to joining BMS, Brian was deputy general counsel at Medarex, Inc., a public biotechnology company that has since been acquired by BMS. At Medarex, Brian was responsible for similar corporate-partnering arrangements, including many collaborations leveraging Medarex’s UltiMab human antibody development technology, as well as broader corporate matters. Brian was also formerly at Schering-Plough Corporation, where he served as senior counsel, licensing, and started his career at Dewey Ballantine LLP in New York City. 


Columbia University

University of Notre Dame
BA, History